Alx Oncology Holdings (ALXO) Retained Earnings (2019 - 2026)

Alx Oncology Holdings has reported Retained Earnings for 8 years, with the latest figure at -$740.7 million in Q1 2026.

• Quarterly Retained Earnings fell 627849.15% year-over-year to -$740.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$740.7 million (down 627849.15% YoY) and the FY2025 annual result came in at -$722.8 million, down 262942.55% from the prior year.
• Retained Earnings fell to -$740.7 million in Q1 2026 per ALXO's latest filing, from -$722.8 million in the prior quarter.
• Over five years, Retained Earnings peaked at $275000.0 in Q4 2024 and troughed at -$740.7 million in Q1 2026.
• A 5-year average of -$231.5 million and a median of -$1.5 million in 2022 frame the typical range for Retained Earnings.
• The widest YoY moves for Retained Earnings: up 321.43% in 2025, down 928427.4% in 2025.
• Over 5 years, Retained Earnings stood at -$325.5 million in 2022, then soared by 100.08% to $256000.0 in 2023, then climbed by 7.42% to $275000.0 in 2024, then sank by 262942.55% to -$722.8 million in 2025, then declined by 2.48% to -$740.7 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$740.7 million, -$722.8 million, and $43000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.